AstraZeneca halts two PhIII hyperkalemia studies intended to spotlight Lokelma’s clinical value
01 Dec 2023
Phase 3Clinical Trial Failure
AstraZeneca announced early Friday morning that it is stopping work on two late-stage trials designed to gather value-added evidence for Lokelma in hyperkalemia, a chronic condition for which the drug is already approved.
The Phase III STABILIZE-CKD trial faced “substantially increased enrolment timelines,” while the Phase III DIALIZE-Outcomes trial reported low event rates. As such, “it was prohibitive to deliver study results within a timeframe to meaningfully advance clinical practice,” the company said in a press release.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.